Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Abstract Background The anti-interleukin 17A agent secukinumab has been approved for the treatment of spondyloarthritis (SpA) patients as an alternative to tumor necrosis factor inhibitors (TNFis). Our aim was to compare long-term treatment persistence and relevant effect modifiers, as well as 6-mon...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Irini D. Flouri, Argyro Repa, Nestor Avgoustidis, Sofia Pitsigavdaki, Eleni Kalogiannaki, Konstantina Kalligianni-Sofikiti, Evgenia Emmanouilidou, Eleni Marolachaki, George Bertsias, Prodromos Sidiropoulos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	Arthritis Research & Therapy
Assuntos:	Spondyloarthritis Secukinumab TNF inhibitors Axial spondyloarthritis Psoriatic arthritis Response
Acesso em linha:	https://doi.org/10.1186/s13075-025-03664-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!